Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial
Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2024-10-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2621 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849320719876358144 |
|---|---|
| author | Heri Nugroho Nurmilawati Nurmilawati Diana Novitasari Lidia Rombeallo Rambu Farah Effendi Reski Reski Intan Surayya Nugroho Agung Daryanto Solomon Putera Raymond Rubianto Tjandrawinata |
| author_facet | Heri Nugroho Nurmilawati Nurmilawati Diana Novitasari Lidia Rombeallo Rambu Farah Effendi Reski Reski Intan Surayya Nugroho Agung Daryanto Solomon Putera Raymond Rubianto Tjandrawinata |
| author_sort | Heri Nugroho |
| collection | DOAJ |
| description |
Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2DM. Methods: A 12-week double-blind, randomized, placebo-controlled clinical trial was conducted with 104 eligible participants. They were assigned to receive DLBS3233 or a placebo along with lifestyle modifications. Various metabolic parameters, including fasting and post-meal plasma glucose levels at two hours, fasting insulin level, HOMA-IR, adiponectin level, lipid profile, superoxide dismutase (SOD) activity, GLUT-4 concentrations, and body weight measurements, were assessed at baseline, Week 6, and Week 12. Safety parameters assessment will include vital signs, liver function, renal function and adverse event. Results: Participants exhibited similar demographic characteristics in both groups. While no significant changes were noted in fasting plasma glucose and most other parameters, the DLBS3233 group significantly reduced 2-hour postprandial glucose at Week 12 (p = 0.026). There were no substantial differences in A1c levels, fasting insulin, insulin resistance, adiponectin levels, or lipid profiles between the two groups at any point in time. Safety parameters, including blood pressure, liver enzymes, heart rate, gamma GT, and serum creatinine, remained comparable between the groups. Conclusion: DLBS3233 showed potential for improving postprandial glucose control in newly diagnosed T2DM individuals. Although significant changes were limited, the study suggests that DLBS3233 could enhance glycemic regulation. The safety evaluation indicated no adverse effects on vital parameters. Further research with larger samples and more prolonged duration is warranted to comprehensively explore DLBS3233’s potential in T2DM management.
|
| format | Article |
| id | doaj-art-36dd78dabfd74e05bc7e357e1a1dbcd5 |
| institution | Kabale University |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-36dd78dabfd74e05bc7e357e1a1dbcd52025-08-20T03:50:00ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322024-10-01563Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical TrialHeri Nugroho0Nurmilawati Nurmilawati1Diana Novitasari2Lidia Rombeallo3Rambu Farah Effendi4Reski Reski5Intan Surayya6Nugroho Agung Daryanto7Solomon Putera8Raymond Rubianto Tjandrawinata9Division Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, IndonesiaDivision Endocrinology, Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro - Dr. Kariadi General Hospital, Semarang, Indonesia1. Dexa Laboratories of Biomolecular Sciences, Cikarang, West Java, Indonesia 2. Atma Jaya Catholic University of Indonesia, Faculty of Biotechnology, Banten, Indonesia Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2DM. Methods: A 12-week double-blind, randomized, placebo-controlled clinical trial was conducted with 104 eligible participants. They were assigned to receive DLBS3233 or a placebo along with lifestyle modifications. Various metabolic parameters, including fasting and post-meal plasma glucose levels at two hours, fasting insulin level, HOMA-IR, adiponectin level, lipid profile, superoxide dismutase (SOD) activity, GLUT-4 concentrations, and body weight measurements, were assessed at baseline, Week 6, and Week 12. Safety parameters assessment will include vital signs, liver function, renal function and adverse event. Results: Participants exhibited similar demographic characteristics in both groups. While no significant changes were noted in fasting plasma glucose and most other parameters, the DLBS3233 group significantly reduced 2-hour postprandial glucose at Week 12 (p = 0.026). There were no substantial differences in A1c levels, fasting insulin, insulin resistance, adiponectin levels, or lipid profiles between the two groups at any point in time. Safety parameters, including blood pressure, liver enzymes, heart rate, gamma GT, and serum creatinine, remained comparable between the groups. Conclusion: DLBS3233 showed potential for improving postprandial glucose control in newly diagnosed T2DM individuals. Although significant changes were limited, the study suggests that DLBS3233 could enhance glycemic regulation. The safety evaluation indicated no adverse effects on vital parameters. Further research with larger samples and more prolonged duration is warranted to comprehensively explore DLBS3233’s potential in T2DM management. http://www.actamedindones.org/index.php/ijim/article/view/2621Type 2 Diabetes MellitusDLBS3233Insulin sensitivityclinical trial |
| spellingShingle | Heri Nugroho Nurmilawati Nurmilawati Diana Novitasari Lidia Rombeallo Rambu Farah Effendi Reski Reski Intan Surayya Nugroho Agung Daryanto Solomon Putera Raymond Rubianto Tjandrawinata Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial Acta Medica Indonesiana Type 2 Diabetes Mellitus DLBS3233 Insulin sensitivity clinical trial |
| title | Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial |
| title_full | Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial |
| title_fullStr | Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial |
| title_full_unstemmed | Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial |
| title_short | Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial |
| title_sort | effectiveness and safety of dlbs3233 in newly diagnosed type 2 diabetes mellitus a 12 week clinical trial |
| topic | Type 2 Diabetes Mellitus DLBS3233 Insulin sensitivity clinical trial |
| url | http://www.actamedindones.org/index.php/ijim/article/view/2621 |
| work_keys_str_mv | AT herinugroho effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT nurmilawatinurmilawati effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT diananovitasari effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT lidiarombeallo effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT rambufaraheffendi effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT reskireski effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT intansurayya effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT nugrohoagungdaryanto effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT solomonputera effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial AT raymondrubiantotjandrawinata effectivenessandsafetyofdlbs3233innewlydiagnosedtype2diabetesmellitusa12weekclinicaltrial |